90 results on '"Jarolim, Petr"'
Search Results
2. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
3. Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial
4. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL
5. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF
6. NT-PROBNP, BODY MASS INDEX, AND HEART FAILURE RISK IN CAMELLIA-TIMI 61
7. Tracking immune correlates of protection for emerging SARS-CoV-2 variants
8. Neutrophil-Lymphocyte Ratio and Clinical Outcomes in 19,697 Patients with Atrial Fibrillation: Analyses from ENGAGE AF-TIMI 48 Trial
9. SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021
10. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
11. TARGETED PROTEOMIC PROFILING OF CARDIOGENIC SHOCK IN THE CARDIAC INTENSIVE CARE UNIT: AN ANALYSIS FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK (CCCTN) REGISTRY
12. CIRCULATING BIOMARKER PATTERNS IN PATIENTS WITH VASODILATORY CARDIOGENIC SHOCK IN THE CARDIAC INTENSIVE CARE UNIT: ANALYSIS FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK (CCCTN) REGISTRY
13. A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48
14. Exercise dynamics of cardiac biomarkers and hemoconcentration in patients with chronic systolic heart failure
15. Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults
16. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry
17. Targeted Delivery of Immunomodulators to Lymph Nodes
18. Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial
19. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial
20. The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease
21. CARDIOVASCULAR BIOMARKERS AND HEART FAILURE RISK IN PATIENTS WITH STABLE ATHEROTHROMBOTIC DISEASE: A NESTED BIOMARKER STUDY FROM TRA 2°P-TIMI 50
22. THE NEUROHORMONAL BASIS OF PULMONARY HYPERTENSION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
23. INFLAMMATORY BIOMARKERS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH STEMI: A NESTED OBSERVATIONAL STUDY FROM LATITUDE-TIMI 60
24. Myocardial Injury and Cardiac Reserve Limitation in Heart Failure with Preserved Ejection Fraction
25. Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction
26. Causes of Troponin Elevation and Associated Mortality in Young Patients
27. PROGNOSTIC VALUE OF BIOMARKER OF COLLAGEN TURNOVER (C-TERMINAL TELOPEPTIDE) IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM MERLIN-TIMI 36
28. 74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis
29. Relationships between Novel Biomarkers and Hemodynamics during Exercise in Heart Failure with Preserved Ejection Fraction
30. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
31. WOMEN WHO EXPERIENCE MYOCARDIAL INFARCTION AT A YOUNG AGE HAVE WORSE SURVIVAL COMPARED WITH MEN
32. CIRCULATING CONCENTRATIONS OF OREXIN A ARE ASSOCIATED WITH LEFT VENTRICULAR REVERSE REMODELING AND CLINICAL OUTCOMES FOLLOWING CARDIAC RESYNCHRONIZATION THERAPY
33. LIPID ABNORMALITIES IN YOUNG PATIENTS WITH MYOCARDIAL INFARCTION
34. TYPE 2 MYOCARDIAL INFARCTION IN YOUNG PATIENTS PORTENDS A WORSE LONG-TERM SURVIVAL
35. Heart rate response to exercise in heart failure patients: The prognostic role of metabolic–chronotropic relation and heart rate recovery
36. Circulating Concentrations of Orexin A Predict Left Ventricular Myocardial Remodeling
37. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease
38. Use of high sensitivity cardiac troponin assays as an adjunct to cardiac stress testing
39. INTERLEUKIN-6 AND THE RISK OF ADVERSE OUTCOMES IN PATIENTS AFTER AN ACUTE CORONARY SYNDROME: OBSERVATIONS FROM THE SOLID-TIMI 52 TRIAL
40. Symposium S24 Molecular Immunohematology
41. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure
42. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
43. Plasma Corin Decreases After Coronary Artery Bypass Graft Surgery and Is Associated With Postoperative Heart Failure: A Pilot Study
44. GALECTIN-3 FOR HEART FAILURE RISK STRATIFICATION IN PATIENTS AFTER ACUTE CORONARY SYNDROMES (ACS): INSIGHTS FROM THE SOLID-TIMI 52 TRIAL
45. PROGNOSTIC UTILITY OF FIBROBLAST GROWTH FACTOR-23 AFTER AN ACUTE CORONARY SYNDROME
46. Cardiac troponin assays in the management of heart failure
47. Diagnostic Performance of ST2 for Differentiating Cardiogenic versus Non-Cardiogenic Pulmonary Edema in Patients Presenting to the Intensive Care Unit with Hypoxic Respiratory Failure
48. Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea
49. Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease
50. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.